Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk MkW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zCO2lEPTB;MD6wNlgxPiEQvF2= NHjWeGtUSU6JRWK=
KS-1 MkHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTBwMEO4N|Uh|ryP MofsV2FPT0WU
TE-11 NUXoT3oxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlP6TWM2OD1yLkC3PFIzKM7:TR?= NWXlbIY5W0GQR1XS
EW-1 MmXJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf0TWM2OD1yLkC4OVg2KM7:TR?= NXnQdmlHW0GQR1XS
HMV-II MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfU[GRSUUN3ME2wMlA5QDR4IN88US=> Mk\nV2FPT0WU
COLO-205 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\yfG9mUUN3ME2wMlExPDV2IN88US=> MkjNV2FPT0WU
ES1 M3f1[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXuRoZKSzVyPUCuNVA3QTZizszN NF\GfXZUSU6JRWK=
GDM-1 MoTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH3BcoZKSzVyPUCuNVM3PzJizszN NH[yemJUSU6JRWK=
ML-2 NGn0OJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETiPGZKSzVyPUCuNVU5QTZizszN NH3tZ2NUSU6JRWK=
Saos-2 MnfyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwMU[1NlYh|ryP MVLTRW5ITVJ?
NCI-H1355 Ml\SS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{exXGlEPTB;MD6xPFE{PSEQvF2= M{HxbHNCVkeHUh?=
G-401 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXqTWM2OD1yLkG4NlMh|ryP NHy1e3dUSU6JRWK=
EW-16 NGHhRYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEWzRpdKSzVyPUCuNVg4PzdizszN NVL0SHhPW0GQR1XS
EW-7 NHz4OpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWLEd3dmUUN3ME2wMlE5QDhzIN88US=> NUn4fHYxW0GQR1XS
NCI-H727 NFf3WmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL4dVBKSzVyPUCuNVk4QTRizszN MmLaV2FPT0WU
LCLC-97TM1 NXPpWlFWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTBwMkC5OVUh|ryP NGi2fotUSU6JRWK=
NCI-H650 Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmr1TWM2OD1yLkKxN|g1KM7:TR?= NFnZTZJUSU6JRWK=
NCI-H2122 NHWwV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;icZZKSzVyPUCuNlMzQTlizszN MlntV2FPT0WU
SK-N-DZ M3fTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVnJR|UxRTBwMkO2PVgh|ryP M{LheXNCVkeHUh?=
HT-29 NGnvcGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkfuTWM2OD1yLkK0NlQ5KM7:TR?= M1LYW3NCVkeHUh?=
LB771-HNC NILDNmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnSNZFKSzVyPUCuNlU6OTVizszN NH7L[ZlUSU6JRWK=
HT-144 M4S4Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXMUlc1UUN3ME2wMlI3OTlzIN88US=> NW\Kb2pOW0GQR1XS
LAN-6 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXFZYJXUUN3ME2wMlI3OzR6IN88US=> MV3TRW5ITVJ?
EW-18 NWGwOIZVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\TTWM2OD1yLkK3NFAyKM7:TR?= NV3EenRVW0GQR1XS
LS-1034 MkjxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXK0RWJsUUN3ME2wMlI4OTN{IN88US=> MnzlV2FPT0WU
EW-11 M{Gyemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml64TWM2OD1yLkK4OFMzKM7:TR?= MkfHV2FPT0WU
SNU-C1 NX23[I9nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDTTWM2OD1yLkK5N|E{KM7:TR?= M2THcXNCVkeHUh?=
RS4-11 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTBwM{O3OVgh|ryP M3GzOXNCVkeHUh?=
ES4 NHvtZmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTBwNEGwN|gh|ryP M3[4eHNCVkeHUh?=
COLO-320-HSR MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTBwNEGzOlgh|ryP MlztV2FPT0WU
NB10 NYH6U2VzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LGO2lEPTB;MD60OVQ{PyEQvF2= M3\USnNCVkeHUh?=
BFTC-905 NF3zWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLuTWM2OD1yLkS2O|U5KM7:TR?= NHG1[HZUSU6JRWK=
A375 NFq0XJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MofoTWM2OD1yLkS3OlE4KM7:TR?= NGXiVVdUSU6JRWK=
SJRH30 M1rnUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1jCfmlEPTB;MD61NFgzOiEQvF2= M{jLdHNCVkeHUh?=
NOS-1 NVPxVVJTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXjTWM2OD1yLkWyNlY4KM7:TR?= MVjTRW5ITVJ?
SIG-M5 M3q4PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HoPGlEPTB;MD61N|U2PyEQvF2= MWLTRW5ITVJ?
DOK MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1frcWlEPTB;MD61OVYh|ryP M1Hl[nNCVkeHUh?=
NB69 Mmr3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLyTWM2OD1yLkW4NlU4KM7:TR?= M3HKV3NCVkeHUh?=
SK-NEP-1 NVHHboxWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fCPGlEPTB;MD62NFI{PiEQvF2= MVfTRW5ITVJ?
SK-MM-2 M4nTUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfHT29mUUN3ME2wMlY2PDlzIN88US=> MXTTRW5ITVJ?
NCI-H358 NUHHc2VyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYfJR|UxRTBwNkewPFIh|ryP Mk[2V2FPT0WU
RH-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mkf6TWM2OD1yLke0PFU6KM7:TR?= NIXzVWZUSU6JRWK=
NH-12 NWPo[IdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LsWGlEPTB;MD63OlA1PiEQvF2= MmrtV2FPT0WU
TE-12 MmTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTBwN{[0PFYh|ryP M{TpfXNCVkeHUh?=
COLO-668 NEOyfWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVW3[ZdZUUN3ME2wMlg1PjZ4IN88US=> MoPpV2FPT0WU
PANC-08-13 M4DEN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLVTWM2OD1yLki2N|c4KM7:TR?= NGGzRYtUSU6JRWK=
HCC2998 M1nwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4\nNGlEPTB;MD64PFI3OyEQvF2= M1fOW3NCVkeHUh?=
ABC-1 NFnSXVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f4fmlEPTB;MD65NFM2OiEQvF2= NXnoZoNMW0GQR1XS
ES6 M{L0c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4X4WGlEPTB;MD65NVA3PiEQvF2= M3zMd3NCVkeHUh?=
SNU-387 NF;n[HBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\vNGlEPTB;MD65PVM6OyEQvF2= NYXUN3NXW0GQR1XS
CMK Mn\QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\RTWM2OD1yLkm5PVI6KM7:TR?= NF3qRYNUSU6JRWK=
SJSA-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13Z[WlEPTB;MT6wN|Y2OyEQvF2= MUPTRW5ITVJ?
SIMA NH3BS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mof0TWM2OD1zLkC2PFI2KM7:TR?= NGTQVIZUSU6JRWK=
ES3 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFwMUKyPVch|ryP MXfTRW5ITVJ?
IGROV-1 NWfse2ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXj1XHBbUUN3ME2xMlE2PDR2IN88US=> MXnTRW5ITVJ?
MEL-JUSO MljsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGLUdW1KSzVyPUGuNVU4PTlizszN MmraV2FPT0WU
T84 M3\WTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{Lt[2lEPTB;MT6yNFkyPCEQvF2= NF7oNXNUSU6JRWK=
CAL-85-1 NFHUSmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHITWM2OD1zLkKzNVM5KM7:TR?= NYTNd3ZNW0GQR1XS
RD M1LZUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnXcolFUUN3ME2xMlI3PDV3IN88US=> MlTWV2FPT0WU
TE-8 MoPlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwM{G0OlIh|ryP NFPIbmdUSU6JRWK=
L-363 MnjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV\yT2pwUUN3ME2xMlM1OjB6IN88US=> MofkV2FPT0WU
EKVX MlXHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTFwM{S1Olgh|ryP MWHTRW5ITVJ?
SK-MEL-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX7JR|UxRTFwNEi1OVYh|ryP M1e0UnNCVkeHUh?=
TGBC24TKB MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4fHb2lEPTB;MT61NFE6OyEQvF2= NGnMeVFUSU6JRWK=
NCI-H1770 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTFwNUGxNVMh|ryP Mn3XV2FPT0WU
HuH-7 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHezVZBKSzVyPUGuOlAxQThizszN MXjTRW5ITVJ?
HL-60 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHpNZRKSzVyPUGuOlY6OjhizszN M2XhR3NCVkeHUh?=
TE-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXhUnZKSzVyPUGuO|A6PDVizszN M3v3VXNCVkeHUh?=
LC-2-ad M1jBO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEXpdYhKSzVyPUGuO|M5QDdizszN M2\0fnNCVkeHUh?=
LB647-SCLC NVjIdZZ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3zLUGlEPTB;MT63OlU5OyEQvF2= NFPubHlUSU6JRWK=
NCI-H2171 M{Ow[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHXLVZJKSzVyPUGuO|c4OTZizszN NXL4[3VOW0GQR1XS
SK-PN-DW MkD2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWrJR|UxRTFwOUGyPVgh|ryP NYDkV3ZWW0GQR1XS
MC-IXC M2P4[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTFwOUi5PEDPxE1? NEn4R5RUSU6JRWK=
LS-513 NXXZbVNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\YT3FkUUN3ME2yMlA2OzB3IN88US=> Mn\QV2FPT0WU
EW-3 MnHES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIPpR|VKSzVyPUKuNFk5PDRizszN MWnTRW5ITVJ?
OPM-2 NFfqZnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTFTWM2OD1{LkGwNkDPxE1? NUfsNJdTW0GQR1XS
LP-1 NILCe4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJwMkW4NFch|ryP NHPu[phUSU6JRWK=
LU-134-A MnG3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33aNmlEPTB;Mj6yO|ch|ryP NYDzVY9HW0GQR1XS
CP66-MEL NIPJ[GlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRTJwMkmwNVQh|ryP MYXTRW5ITVJ?
HCC1143 NY\SZ|Y6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2[0TGlEPTB;Mj60OVM3QCEQvF2= MkC4V2FPT0WU
LOXIMVI MnTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjzU|dKSzVyPUKuOlAzOSEQvF2= Moq3V2FPT0WU
TE-10 NGTBb3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1H0eGlEPTB;Mj63NFg{QCEQvF2= Moq0V2FPT0WU
NCI-H1882 M4jSfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTJwN{WyNlch|ryP MV;TRW5ITVJ?
CHP-126 NYLsNoQ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETBZXJKSzVyPUKuO|Y{OTdizszN MVnTRW5ITVJ?
NCI-H1623 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTJwOUKwNlQh|ryP MojyV2FPT0WU
GB-1 MnvzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTJwOUO0NFQh|ryP MnfwV2FPT0WU
RCC10RGB M3XJcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUXJR|UxRTJwOUWyPFEh|ryP NYfoTVJ2W0GQR1XS
NCI-H2141 M1rEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\DTWM2OD1{Lkm2PFk3KM7:TR?= Ml7tV2FPT0WU
GI-ME-N MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1jtemlEPTB;Mz6wNFU3PSEQvF2= NU\Se2pWW0GQR1XS
NCI-H526 NU\XOINqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTDbHRKSzVyPUOuNFQxQDVizszN NVXoZZFTW0GQR1XS
NCI-H747 M{C5eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1T5TmlEPTB;Mz6wOFk6OiEQvF2= MknnV2FPT0WU
SNU-423 M3zmemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUCx[lQ{UUN3ME2zMlIxOzF|IN88US=> MkLLV2FPT0WU
A427 NFXQUW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfPNXp5UUN3ME2zMlI2Pjl7IN88US=> NX;0WnkyW0GQR1XS
CAL-12T NILnT4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mm[5TWM2OD1|LkSwO|E{KM7:TR?= NYqzRpZMW0GQR1XS
LU-99A NFnqZoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlXUTWM2OD1|LkS3NVA2KM7:TR?= MVTTRW5ITVJ?
MS-1 NHyxNpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1rDRWlEPTB;Mz61N|QzQSEQvF2= M4ftUHNCVkeHUh?=
SK-LU-1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUXJR|UxRTNwN{[yPVUh|ryP M4PNN3NCVkeHUh?=
SW837 NHy4OZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlnwTWM2OD1|Lke2N|M{KM7:TR?= NIGzZ2JUSU6JRWK=
ES8 NXewPWZsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVnNOmF2UUN3ME2zMlg{QDd5IN88US=> NGXZPGJUSU6JRWK=
MZ2-MEL M2D0PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mln3TWM2OD1|LkmyNFg3KM7:TR?= MVTTRW5ITVJ?
TGW NUXoflN4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jpVmlEPTB;ND6wNVMyOSEQvF2= Mom4V2FPT0WU
GP5d MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:3TWM2OD12LkC1N|YzKM7:TR?= MV3TRW5ITVJ?
BB49-HNC MmjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRwMUWyNVMh|ryP NF2ydG9USU6JRWK=
NB13 NUDiSG9NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1m5N2lEPTB;ND6yOlg5PyEQvF2= MmjYV2FPT0WU
NTERA-S-cl-D1 NH3RUJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mom3TWM2OD12LkK4OlE2KM7:TR?= MY\TRW5ITVJ?
NCI-H1648 M1n6Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTRwMkm4NVkh|ryP MUjTRW5ITVJ?
LCLC-103H NYf0Um9ST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3L[FkxUUN3ME20MlMzOTl3IN88US=> M3jtOnNCVkeHUh?=
LS-411N Mn;0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXrJR|UxRTRwNES4PFUh|ryP M2GyNXNCVkeHUh?=
NCI-H1092 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml73TWM2OD12LkS1Olg4KM7:TR?= MmfoV2FPT0WU
PANC-10-05 MkjFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mlv6TWM2OD12Lk[5PFQh|ryP MonWV2FPT0WU
DK-MG MlO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTRwOEC5N|Mh|ryP MkXKV2FPT0WU
OVCAR-5 MmXaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HZeWlEPTB;ND64NVIzPiEQvF2= NVXET2xZW0GQR1XS
CAL-39 MontS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4X2W2lEPTB;ND64O|Y4KM7:TR?= MXXTRW5ITVJ?
TE-441-T NXvRTphxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mkf5TWM2OD12LkmwOVM4KM7:TR?= MoKyV2FPT0WU
MOLT-16 MkXYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HrXmlEPTB;ND65OVI2OyEQvF2= MnXZV2FPT0WU
MCF7 NXrXeGVkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYHHXXlEUUN3ME21MlE1PTF5IN88US=> NIraRVBUSU6JRWK=
CAPAN-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTVwMkW3NFch|ryP MVPTRW5ITVJ?
PSN1 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoLyTWM2OD13LkK3NlM2KM7:TR?= NV;5N|VoW0GQR1XS
NCI-H292 M2GydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml23TWM2OD13LkOwNFQ1KM7:TR?= Mn\mV2FPT0WU
CPC-N NWDxUm0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTVwM{m0NVkh|ryP MW\TRW5ITVJ?
DoTc2-4510 MojRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{OzWmlEPTB;NT60OVM4OSEQvF2= MY\TRW5ITVJ?
LB1047-RCC NGjRWYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVz6VYdqUUN3ME21MlU2QTN|IN88US=> MnfwV2FPT0WU
MHH-ES-1 NWntc2xUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTVwNUm5NFch|ryP NHvLTXBUSU6JRWK=
NMC-G1 Mo\WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFr4W3NKSzVyPUWuO|AzOjdizszN M{XK[XNCVkeHUh?=
SW1710 NXqyc5l7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37rUWlEPTB;NT63OFc2OSEQvF2= MkXPV2FPT0WU
YAPC MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\JeWlEPTB;NT63OlIxOSEQvF2= M{H6d3NCVkeHUh?=
22RV1 NGO5[JJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3myUmlEPTB;NT64NFAyQSEQvF2= NFjFbZhUSU6JRWK=
COLO-679 NG\ZUFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;xSWlEPTB;NT64PFk1QCEQvF2= NEnDVFJUSU6JRWK=
TCCSUP NWXUeop5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDhOmJVUUN3ME21Mlk{OjV7IN88US=> NXvafpYzW0GQR1XS
C2BBe1 M1HKPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX5[INKSzVyPUWuPVM6PyEQvF2= MmrMV2FPT0WU
TE-15 NEfaUZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r4eWlEPTB;Nj6wOlYxPSEQvF2= NVroPGl3W0GQR1XS
SCLC-21H MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXZTWM2OD14LkGwPFQ{KM7:TR?= M{W0SXNCVkeHUh?=
EoL-1-cell MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDyWGVKSzVyPU[uNVY2PjNizszN NIG4UnFUSU6JRWK=
NKM-1 MmTIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV:4VpRRUUN3ME22MlE3PzFizszN NXnPNIxoW0GQR1XS
NCI-H1304 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTZwMke0Nlgh|ryP NGrmdVlUSU6JRWK=
NB6 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1j0Z2lEPTB;Nj6yPVYzOiEQvF2= MUHTRW5ITVJ?
NALM-6 NITWcVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYSwO5pQUUN3ME22MlM{OjNizszN M4XHT3NCVkeHUh?=
NCI-H522 NUXjW40yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTZwM{OzNFYh|ryP NVfiVYNQW0GQR1XS
MV-4-11 NH\Eb2lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHiTWM2OD14LkO3NFc6KM7:TR?= MoXvV2FPT0WU
LB2241-RCC MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnn5TWM2OD14LkO4OlY4KM7:TR?= MUXTRW5ITVJ?
NCI-H1417 NYjzXGZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfWcHpKSzVyPU[uOFA5PDdizszN NF32Z|NUSU6JRWK=
HT-1197 NUnMe5lRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nPcGlEPTB;Nj61O|EzOiEQvF2= NGC4ZoFUSU6JRWK=
P30-OHK MmH3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofSTWM2OD14Lk[yO|ch|ryP M1rnRnNCVkeHUh?=
ALL-PO M1rnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHrseXVKSzVyPU[uO|E6OTZizszN NIKweJJUSU6JRWK=
OVCAR-4 NYXiRYo2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzwTWM2OD14Lke1OFA2KM7:TR?= MV;TRW5ITVJ?
HCC2157 M2XsS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4m2Z2lEPTB;Nj63O|Q4PSEQvF2= M{TvTHNCVkeHUh?=
NCI-H838 NYrHR|VwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUnJR|UxRTZwOU[0PUDPxE1? MmD1V2FPT0WU
NCI-H1299 NF7HWZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjYTWM2OD14Lkm3NFkh|ryP MoKxV2FPT0WU
SW954 NV\TcXd5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\FN2lEPTB;Nz6yNFA3QCEQvF2= M3\NO3NCVkeHUh?=
NCI-H441 MnHYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DHSmlEPTB;Nz6zOFA3PSEQvF2= NV3vRWc1W0GQR1XS
SK-MEL-2 M4naWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTdwNEizO|Mh|ryP M3XSZnNCVkeHUh?=
KARPAS-45 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXnCXXNxUUN3ME23MlY2QTJ7IN88US=> M1TRfnNCVkeHUh?=
CAL-54 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXmfpFnUUN3ME23MlgzQTd5IN88US=> NY\iOWw{W0GQR1XS
KYSE-180 NWLKR4hwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXPoe41TUUN3ME23Mlg5QTRzIN88US=> NXTOb2dCW0GQR1XS
NCI-H187 NFzUXYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XwSWlEPTB;Nz65OVk1PyEQvF2= NXvLSFgxW0GQR1XS
RT-112 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D0eWlEPTB;OD6wPVY4PyEQvF2= MlXUV2FPT0WU
NCI-H1437 MoDZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\1TWM2OD16LkC5O|k2KM7:TR?= MX3TRW5ITVJ?
SNU-449 M3uwbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUjGbJB6UUN3ME24MlI5Ojd{IN88US=> NHTVXlJUSU6JRWK=
HCC1187 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2D5XmlEPTB;OD6yPVM6OSEQvF2= MoHRV2FPT0WU
NCI-H2030 NXLsNVVXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{DnT2lEPTB;OD6zO|cyPCEQvF2= NFT1cYtUSU6JRWK=
HuO-3N1 NH;RSW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HkVmlEPTB;OD6zO|g1PCEQvF2= MkGwV2FPT0WU
COLO-792 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTFU2lKSzVyPUiuOFE2OjdizszN MXzTRW5ITVJ?
MIA-PaCa-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWrJR|UxRThwOEW1NFgh|ryP NYfZeotJW0GQR1XS
SK-N-FI Mn;zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnzGTWM2OD17LkC0NlUh|ryP MWTTRW5ITVJ?
MMAC-SF MoPES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1q4T2lEPTB;OT6wPVc2OSEQvF2= NUPxfYJiW0GQR1XS
NCI-H28 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjwTWM2OD17LkGwOFY6KM7:TR?= MmPBV2FPT0WU
ETK-1 NVfiNHZ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGPCSYRKSzVyPUmuNlk6PzRizszN NFy0NXpUSU6JRWK=
NCI-H1993 NFvQOplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nYTWlEPTB;OT60OFI3OSEQvF2= MYjTRW5ITVJ?
no-11 M3zRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTXTWM2OD17LkS3NVIh|ryP MXHTRW5ITVJ?
ChaGo-K-1 NVPyeVhrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHXmXnFKSzVyPUmuOVE2QDNizszN NYH0V|NRW0GQR1XS
NCCIT NV;tPYN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmXTTWM2OD17LkWzNVY6KM7:TR?= M2jRR3NCVkeHUh?=
SAS NWnMRos5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTFyLkK0PEDPxE1? M3P3N3NCVkeHUh?=
A673 NEjj[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEO4OVhKSzVyPUGwMlM4ODRizszN Mm\oV2FPT0WU
NCI-H1522 M{HCPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWfjZmVSUUN3ME2xNE4{PzB5IN88US=> MUfTRW5ITVJ?
NCI-H810 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\ROGlEPTB;MUCuN|kxPyEQvF2= M3rZdXNCVkeHUh?=
IST-MES1 NX3kNI96T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml;0TWM2OD1zMD60OVY1KM7:TR?= MWHTRW5ITVJ?
GR-ST Mmr0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFK0VGNKSzVyPUGwMlUxOjRizszN NV\ORVNFW0GQR1XS
SUP-T1 Mne1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTFyLkezNVch|ryP NV\KU2t2W0GQR1XS
NB5 NFPr[|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2D1PGlEPTB;MUCuPVAzOiEQvF2= MYPTRW5ITVJ?
MZ1-PC NUnsOWZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzyTWZ[UUN3ME2xNE46PTdzIN88US=> NW\XO4R2W0GQR1XS
SK-CO-1 M{PKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vUZmlEPTB;MUCuPVk{OSEQvF2= NUnSdGpPW0GQR1XS
Capan-2 NGTrSJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFnvU2RKSzVyPUGxMlMyQThizszN MnexV2FPT0WU
697 NUj5T5poT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHTTWM2OD1zMT62O|U4KM7:TR?= NUjtcYt3W0GQR1XS
REH MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTFzLke0OVEh|ryP NUmyd5BSW0GQR1XS
GI-1 M3;Xd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXsV4pKSzVyPUGxMlg3OTVizszN M4\sN3NCVkeHUh?=
BB65-RCC MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDSTWM2OD1zMj6wPVE3KM7:TR?= NIXBSZpUSU6JRWK=
NCI-H1651 MmHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3H4dWlEPTB;MUKuNlQ4QCEQvF2= Mk\PV2FPT0WU
NCI-H1618 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3iTWM2OD1zMj6zPVc3KM7:TR?= M4XMPHNCVkeHUh?=
NCI-H2081 NFGzXJlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzKToRKSzVyPUGyMlYyPDFizszN M1HZV3NCVkeHUh?=
GCIY MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPyTWM2OD1zMj63NlE{KM7:TR?= M3fKfHNCVkeHUh?=
NY NG\iRW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTF|LkC2OFMh|ryP MVTTRW5ITVJ?
PANC-03-27 MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1W3NWlEPTB;MUOuNFgxPyEQvF2= NIjXTpZUSU6JRWK=
BHY MmjlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3XPN2lEPTB;MUOuNlEzOSEQvF2= MoL5V2FPT0WU
SK-OV-3 NVTZdod{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoLmTWM2OD1zMz6zO|Y{KM7:TR?= M2ixUnNCVkeHUh?=
5637 NGi3dWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmf5TWM2OD1zMz63O|U6KM7:TR?= MoPTV2FPT0WU
LC-1F M2TNOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF2LkCzOVYh|ryP MYDTRW5ITVJ?
SNB75 NXjRb4ZrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELuWZNKSzVyPUG0MlA{QDNizszN MnuzV2FPT0WU
CHP-212 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4XLS2lEPTB;MUSuNFQ3PCEQvF2= NWjEd2xJW0GQR1XS
HT-1376 NX6wV5pNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq1Om1KSzVyPUG0MlEyOjZizszN MoPuV2FPT0WU
MONO-MAC-6 NH:2U5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTF2LkG1NFIh|ryP M4G3eXNCVkeHUh?=
CA46 NHO3OIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIP0WG5KSzVyPUG0MlE5OjdizszN MmqwV2FPT0WU
SCC-15 NUXnOm5LT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTVOHpKSzVyPUG0MlU2QDNizszN NEHnc|lUSU6JRWK=
ATN-1 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoCzTWM2OD1zND62OlI4KM7:TR?= MkD5V2FPT0WU
NCI-H2405 NWXQU3U3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4XXXmlEPTB;MUSuPFE2PyEQvF2= Mm\BV2FPT0WU
NCI-H716 M3TScWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkLPTWM2OD1zND64OFk{KM7:TR?= NUjiXYkyW0GQR1XS
SW620 MljNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFf2VFlKSzVyPUG0MlkxOTRizszN MVfTRW5ITVJ?
NCI-H226 NFr5XIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF2LkmwPFUh|ryP NX;Re5lYW0GQR1XS
SW962 NIe4VZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVnJR|UxRTF2Lkm0N|Ih|ryP NYTGOHl7W0GQR1XS
KYSE-150 MmC3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTF2Lkm1OUDPxE1? MojJV2FPT0WU
OCUB-M MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\JfWlEPTB;MUSuPVg5OyEQvF2= MmfBV2FPT0WU
ES7 NIrpTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PRc2lEPTB;MUWuNFk5PCEQvF2= MojmV2FPT0WU
SW1463 NGPLZZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF3LkSyNlMh|ryP MXXTRW5ITVJ?
CAKI-1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE[zVpVKSzVyPUG1MlU{PDZizszN M2C3bXNCVkeHUh?=
MKN28 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH[3VHBKSzVyPUG1MlU1PzlizszN MX;TRW5ITVJ?
SW13 Mn;pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVz0SXZ[UUN3ME2xOU43OThizszN MnnZV2FPT0WU
A3-KAW NHThTpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jMV2lEPTB;MUWuPVY6PyEQvF2= NFm4RoFUSU6JRWK=
LU-65 NH:5WHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoXkTWM2OD1zNT65O|Y5KM7:TR?= NUm2VVJiW0GQR1XS
Calu-1 NX7uPJBTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkWwTWM2OD1zNj6wN|Y5KM7:TR?= MlXiV2FPT0WU
ST486 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXENW9KSzVyPUG2MlA1OzFizszN MV7TRW5ITVJ?
BB30-HNC NF3NR|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\V[2lEPTB;MU[uNVI1PiEQvF2= NFzJdGRUSU6JRWK=
EGI-1 NULQfHRMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TnbmlEPTB;MU[uOFQ3KM7:TR?= NY\tdVF1W0GQR1XS
SH-4 NX3keYZ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFX5bVFKSzVyPUG2MlQ4OzFizszN NXnTNpBFW0GQR1XS
MN-60 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M322UmlEPTB;MUeuNlI6PyEQvF2= M{XZbnNCVkeHUh?=
MPP-89 M2H3Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUnMcI5bUUN3ME2xO{4zPDV7IN88US=> NV\Ye217W0GQR1XS
A2780 NX;nRZlsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2HCTmlEPTB;MUeuOFE{QSEQvF2= M2LJZnNCVkeHUh?=
Daoy MkH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUflPXpvUUN3ME2xO{41Pjl3IN88US=> NUL4O2ZHW0GQR1XS
NCI-H2126 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfhPZFKSzVyPUG3MlQ4PzFizszN Mn\sV2FPT0WU
NCI-H1563 MmjpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPiTWM2OD1zNz60PVE4KM7:TR?= NFnGPYRUSU6JRWK=
8-MG-BA NXq0cYpqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVPJR|UxRTF5Lk[2OFgh|ryP Mk\MV2FPT0WU
786-0 Mo\OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTNTWM2OD1zNz64N|U{KM7:TR?= M3LHTXNCVkeHUh?=
AM-38 NEnkTFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYj3bGE6UUN3ME2xO{46OzB4IN88US=> MWTTRW5ITVJ?
COLO-824 M3qzd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIGzdI1KSzVyPUG4MlQ1OzZizszN NWjKVoFFW0GQR1XS
SK-MEL-30 NV\zbY9GT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1uyfGlEPTB;MUiuOVA5OiEQvF2= MVHTRW5ITVJ?
CESS NXzoV5E3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHGzbZFKSzVyPUG4Mlc3ODlizszN MkPEV2FPT0WU
BL-70 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmPKTWM2OD1zOD64NVU3KM7:TR?= M4rITHNCVkeHUh?=
NCI-H2170 MoDKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV\JR|UxRTF6LkmxO|kh|ryP M4\QO3NCVkeHUh?=
HT-3 MkTZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTF6Lkm4N{DPxE1? NYXHNGNSW0GQR1XS
BOKU NVvyXoZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTF7LkCzPFEh|ryP Moe4V2FPT0WU
HPAF-II M2K3emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zE[mlEPTB;MUmuN|AyPSEQvF2= MkHKV2FPT0WU
KGN M2SwPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1nuXGlEPTB;MUmuOFc3PSEQvF2= NFrDV2VUSU6JRWK=
MC-CAR NYnN[FBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrWTWM2OD1zOT62N|E{KM7:TR?= NXLlbVZCW0GQR1XS
BHT-101 NF\aOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWTQNnlLUUN3ME2xPU44PzdizszN NFXPRmdUSU6JRWK=
SW1783 M4fq[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn;yTWM2OD1zOT63PFA3KM7:TR?= MknCV2FPT0WU
KP-N-YN NUXNc3pKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFzLSXNKSzVyPUKwMlAzPjJizszN M1HxO3NCVkeHUh?=
LU-165 M1fVRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvRUVFKSzVyPUKwMlU2PzFizszN M1TrNXNCVkeHUh?=
GOTO MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV;Tcm5{UUN3ME2yNE43PDVzIN88US=> MYjTRW5ITVJ?
EFM-19 MoLrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvUUnE4UUN3ME2yNU4xPzF4IN88US=> NUTCZmxEW0GQR1XS
CTV-1 M37PNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\6TWM2OD1{MT6xNFU1KM7:TR?= NXLRfmxJW0GQR1XS
HEL NGXNU4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnTkTWM2OD1{MT60NlE3KM7:TR?= MnXmV2FPT0WU
SNU-C2B M4[5Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHyZlFnUUN3ME2yNU41OjZizszN Mo\qV2FPT0WU
ECC4 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTOTWM2OD1{MT63NFch|ryP NFjnWYpUSU6JRWK=
NEC8 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkHLTWM2OD1{MT64N|Y5KM7:TR?= M1LKdXNCVkeHUh?=
KMOE-2 NXnkdIc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXzTGdKSzVyPUKxMlg6OjFizszN MWXTRW5ITVJ?
NCI-H524 Mnr1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mli4TWM2OD1{Mj6wPFA5KM7:TR?= MWrTRW5ITVJ?
WSU-NHL M2CzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPpTWM2OD1{Mj6xOVc4KM7:TR?= NUfI[4hqW0GQR1XS
SF126 M1LPU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVL3RVlGUUN3ME2yNk4zPDZ7IN88US=> MV7TRW5ITVJ?
HOP-92 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHLsd4tKSzVyPUKyMlMyPjdizszN NFzDOoNUSU6JRWK=
CTB-1 NVvFWYU3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUHJR|UxRTJ{LkS2O|ch|ryP NVvCUI1pW0GQR1XS
KYSE-270 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfWdJlWUUN3ME2yNk46OzV5IN88US=> Mo\SV2FPT0WU
SK-MEL-24 M4\Tbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfWTm86UUN3ME2yN{4yQDdizszN M2XjfnNCVkeHUh?=
Calu-3 NUTPTnBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFq5W3pKSzVyPUKzMlIyOjhizszN NEfWbXNUSU6JRWK=
GAMG NUDDZ5VLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnq4TWM2OD1{Mz6yN|Y4KM7:TR?= Ml;qV2FPT0WU
SW1573 NIX3eYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrsTWM2OD1{Mz63OFE2KM7:TR?= NEnpPZBUSU6JRWK=
MHH-NB-11 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXTSnJjUUN3ME2yOE4xOTl2IN88US=> M1jUWHNCVkeHUh?=
TK10 MmDxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWTJR|UxRTJ2LkWwNVMh|ryP MXzTRW5ITVJ?
LB373-MEL-D M4XIVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;WWGlEPTB;MkSuOlA3PCEQvF2= NWrobYZ6W0GQR1XS
KALS-1 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\SOnF{UUN3ME2yOE44OzJ5IN88US=> MWXTRW5ITVJ?
HUTU-80 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ3LkiwN|Ih|ryP MXnTRW5ITVJ?
HuP-T3 NVjxeHBkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PzSmlEPTB;Mk[uNVY4PCEQvF2= MVLTRW5ITVJ?
OE19 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{LjNmlEPTB;Mk[uNlE2OyEQvF2= NYXRV44zW0GQR1XS
J82 NHHkWJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULydmJLUUN3ME2yOk4zPDdzIN88US=> M1LMTnNCVkeHUh?=
DU-4475 NYfvZ29kT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzHcWR1UUN3ME2yOk4{QDF7IN88US=> MWLTRW5ITVJ?
DMS-53 NULtd5pxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTJ4LkWxN|gh|ryP M{PwVXNCVkeHUh?=
COLO-741 NFWwfYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITj[GNKSzVyPUK2Mlg{PDRizszN NHXWbppUSU6JRWK=
SW48 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXpTWM2OD1{Nj64PFIh|ryP MnHzV2FPT0WU
IGR-1 M2jp[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTJ4LkmzN|Qh|ryP M2nzbHNCVkeHUh?=
639-V Mm[wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2PTXWlEPTB;MkeuNFI1PSEQvF2= NUPuT|JzW0GQR1XS
LK-2 NILXN5ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYHHcIxrUUN3ME2yO{41OTRzIN88US=> M4HEe3NCVkeHUh?=
NCI-H2347 MkXuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHv5[m1KSzVyPUK3Mlk3QTlizszN NH\FdVdUSU6JRWK=
NCI-H2228 NYOxbGFQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUfJR|UxRTJ6LkC5NFUh|ryP MWLTRW5ITVJ?
LS-123 MkW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3OeoZKSzVyPUK4MlEzPjJizszN M3PKW3NCVkeHUh?=
U031 NFPJe4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPMeFFKSzVyPUK4MlI2OiEQvF2= NWPhPJJJW0GQR1XS
NCI-H1792 NXTMfGhpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1ju[mlEPTB;MkiuOFczOSEQvF2= MYrTRW5ITVJ?
NCI-H2087 NIrQOYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjvTWM2OD1{OD63OVUzKM7:TR?= M4OxdHNCVkeHUh?=
NCI-H2342 M3\WeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYDJR|UxRTJ7LkWyNFgh|ryP M{fGd3NCVkeHUh?=
SW626 NWTQNI1mT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYXw[3pqUUN3ME2yPU44PTZizszN M{T3SXNCVkeHUh?=
LB2518-MEL Ml3pS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\Nc21pUUN3ME2yPU45OTVizszN NUjvSodMW0GQR1XS
RXF393 NXTzVGFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3r1OGlEPTB;M{CuNFk2OiEQvF2= MXjTRW5ITVJ?
LC4-1 MkPuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTWTWM2OD1|MD6zNFkzKM7:TR?= MULTRW5ITVJ?
NCI-H1694 NI\YZ3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;OTFNKSzVyPUOwMlY3OjRizszN M3nCenNCVkeHUh?=
K5 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVPMN2hmUUN3ME2zNE46PzB{IN88US=> MXHTRW5ITVJ?
HDLM-2 NEXlbYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4e3cWlEPTB;M{CuPVczPSEQvF2= MVnTRW5ITVJ?
BCPAP NX6wWJJwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;3WWlEPTB;M{GuPFM4QSEQvF2= MlPoV2FPT0WU
BC-3 Mn7WS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjCVJpbUUN3ME2zNk4yPDB|IN88US=> NXPxcXpjW0GQR1XS
LB996-RCC M1yxUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXXJR|UxRTN{LkKzOVgh|ryP NIDNVldUSU6JRWK=
NCI-H2009 M3XXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTN{LkS5PFEh|ryP NFnid4hUSU6JRWK=
HTC-C3 NXvke4pST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoCyTWM2OD1|Mz63OVE6KM7:TR?= MUXTRW5ITVJ?
LAMA-84 NYDNWlBjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2C2[WlEPTB;M{SuOFQxPyEQvF2= NVHXb|FxW0GQR1XS
CCRF-CEM NGjpcphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfoWW1KSzVyPUO0MlU4OTVizszN M1i2WnNCVkeHUh?=
AN3-CA NF7wOlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDYdXVtUUN3ME2zOU4xPTZ6IN88US=> MmHvV2FPT0WU
NCI-H1734 NU[2PWtoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LPfmlEPTB;M{WuNlU3OSEQvF2= Mn\rV2FPT0WU
Ca-Ski MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVn0SpliUUN3ME2zOU41OTBzIN88US=> M1zm[3NCVkeHUh?=
U-266 MnrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnGTWM2OD1|NT62NVE1KM7:TR?= MnLqV2FPT0WU
SBC-5 M{XZc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzwWVVlUUN3ME2zOU44PzhzIN88US=> MoLtV2FPT0WU
GT3TKB NF3XcXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTN5LkGxOUDPxE1? Mn;rV2FPT0WU
MDA-MB-175-VII Mon6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3zaNmlEPTB;M{euNlI1QCEQvF2= MX\TRW5ITVJ?
PFSK-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF:0XXRKSzVyPUO3MlI1OzVizszN M4jKOnNCVkeHUh?=
IMR-5 NFHXZ2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIXpb5JKSzVyPUO3MlI1QDdizszN NI\2cIpUSU6JRWK=
Daudi NHPtdJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGPzU3VKSzVyPUO3MlM2QTdizszN NGPNUXZUSU6JRWK=
A498 NG\YVGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rMNGlEPTB;M{euO|IyQCEQvF2= M3v5dHNCVkeHUh?=
SCC-4 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYP4eHBTUUN3ME2zO{44QDR|IN88US=> NXfYNmdTW0GQR1XS
COLO-680N MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUDZT5ZsUUN3ME2zPE4zQDh3IN88US=> MVjTRW5ITVJ?
SK-MES-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NETlTplKSzVyPUO4MlMzOTVizszN NWDxW3NuW0GQR1XS
SR NHTsTGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3RTWM2OD1|OD61OFk2KM7:TR?= NGe0bGtUSU6JRWK=
LNCaP-Clone-FGC MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTN6LkW2N|ch|ryP NIjz[3pUSU6JRWK=
SK-HEP-1 MmqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTN6Lke4NlIh|ryP NHfvO2FUSU6JRWK=
BPH-1 MoXNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnPTXFKSzVyPUO4Mlg{OjlizszN NEPBO|NUSU6JRWK=
NCI-H1755 NWTM[ZE4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTlTWM2OD1|OT61PFE4KM7:TR?= NIrnSmtUSU6JRWK=
LXF-289 M1fsbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fLUGlEPTB;M{muPFA5PCEQvF2= MVzTRW5ITVJ?
SW1088 NE\LT5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mkj0TWM2OD12MD6yNVA4KM7:TR?= NVy0foRHW0GQR1XS
MOLT-4 NHLaXIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTRyLkK5NFEh|ryP NXHuc4hIW0GQR1XS
AsPC-1 M2rpXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4DsS2lEPTB;NECuOFU5OyEQvF2= Mnn0V2FPT0WU
HOP-62 M17RWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGK3fIFKSzVyPUSwMlY2PjhizszN M4HlTXNCVkeHUh?=
A172 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mle1TWM2OD12MD64OVEyKM7:TR?= NGCwR4pUSU6JRWK=
SN12C M1H3ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTRyLkmzPFUh|ryP NFfBVIlUSU6JRWK=
MDA-MB-231 MnnFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTRyLkm4PVgh|ryP Ml24V2FPT0WU
RPMI-2650 M2jWb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmO2TWM2OD12MT6xOVk{KM7:TR?= MVzTRW5ITVJ?
KYSE-140 NYH1R4VqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIThO5NKSzVyPUSxMlgyOjNizszN NVXFbnVwW0GQR1XS
KINGS-1 Mk\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYfJR|UxRTR{LkS2PVch|ryP M3;Gd3NCVkeHUh?=
HSC-3 NGTJV2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrCTWM2OD12Mj62OlYyKM7:TR?= M3nveXNCVkeHUh?=
PC-14 MnHvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXT1NIN5UUN3ME20N{4yQDh{IN88US=> NXrWeoVpW0GQR1XS
COR-L105 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITNRY1KSzVyPUSzMlY2ODJizszN Mn\OV2FPT0WU
BE-13 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn3ITWM2OD12ND6yN|cyKM7:TR?= NFzHdIRUSU6JRWK=
NCI-H661 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4H4O2lEPTB;NESuNlk2QCEQvF2= M363bXNCVkeHUh?=
IST-MEL1 NUj2VmNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjHUVdKSzVyPUS0MlM2QTlizszN M{TsZnNCVkeHUh?=
HCC1806 M3[wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MW\JR|UxRTR2LkW4O|Mh|ryP M1\BOnNCVkeHUh?=
COLO-800 NWDYbVVZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPzSmNKSzVyPUS0Mlg1PTNizszN NUOwO|RZW0GQR1XS
IST-SL2 Mkn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MofiTWM2OD12NT6xNlQ4KM7:TR?= NIXFcYRUSU6JRWK=
8305C M3Ttbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTR3LkOwPUDPxE1? MmfiV2FPT0WU
UACC-62 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXkTWM2OD12Nj6yPFc2KM7:TR?= MWHTRW5ITVJ?
COR-L23 NX\lS2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPsfpNyUUN3ME20O{4yQTlizszN NXzmRmdFW0GQR1XS
EFE-184 M2jmcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjYO|ZKSzVyPUS3MlM5QCEQvF2= MYPTRW5ITVJ?
DMS-114 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEW2NopKSzVyPUS3MlQyPDlizszN NFjrSpdUSU6JRWK=
KYSE-520 NWK3S3Y1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LEc2lEPTB;NEiuOVMyPSEQvF2= MXzTRW5ITVJ?
SNG-M M1LRSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjJZWRKSzVyPUS5MlQ{PCEQvF2= MWLTRW5ITVJ?
A2058 NIqzdWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGfBeY9KSzVyPUS5MlQ5QDVizszN NWLJR5NOW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents individually and in order:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID